Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shandong Weigao Group Medical Polymer Co Equity-to-Asset?
Shandong Weigao Group Medical Polymer CoSHWGF -2.42%59 Equity-to-Asset is 0.67 as of Dec. 2025, which is 2% above its 10-year median of 0.66. GuruFocus rates SHWGF with a GF Score™ of 59/100 and a GF Value™ of $0.80 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 55.7% on this metric.
SHWGF's Equity-to-Asset is ranked better than 55.7% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs SHWGF: 0.67
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Shandong Weigao Group Medical Polymer Co Equity-to-Asset Related Terms
Shandong Weigao Group Medical Polymer Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co Equity-to-Asset Chart
Shandong Weigao Group Medical Polymer Co Annual Data
SHWGF vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Equity-to-Asset falls into.
Shandong Weigao Group Medical Polymer Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co (SHWGF) has a Equity-to-Asset of 0.67 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is near median its historical median of 0.66. Over the past decade, Shandong Weigao Group Medical Polymer Co's Equity-to-Asset has ranged from 0.61 to 0.80. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #377 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 44.3%.
Is Shandong Weigao Group Medical Polymer Co's Equity-to-Asset too high?
Shandong Weigao Group Medical Polymer Co's current Equity-to-Asset of 0.67 is near median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.80. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Shandong Weigao Group Medical Polymer Co's value of 0.67 is 4.7% above this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #377 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #377 out of 851 companies for Equity-to-Asset. This puts Shandong Weigao Group Medical Polymer Co in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Shandong Weigao Group Medical Polymer Co's value of 0.67 is 4.7% above this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own Equity-to-Asset has ranged from 0.61 to 0.80 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 0.64, Shandong Weigao Group Medical Polymer Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current Equity-to-Asset of 0.67 is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current Equity-to-Asset is 0.67, which is near median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.80, compared to a current price of $0.43 — trading 46.1% below its estimated fair value. The current Equity-to-Asset is 0.67, which is near median its 10-year median of 0.66 and 4.7% above the Medical Devices & Instruments industry median of 0.64. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGF), the current Equity-to-Asset is 0.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGF) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $0.43 is trading 46.1% below its estimated GF Value™ of $0.80.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGF:
Equity-to-Asset: 0.67 (near median its 10-year median of 0.66)
GF Value™: $0.80 vs. price of $0.43 (46.1% below fair value)
Industry Position: 4.7% above the Medical Devices & Instruments median (#377 of 851)
No single metric tells the full story. See the SHWGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
59GF Score
Get the complete analysis for SHWGF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGF has been successfully added to your 
